Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
Clarity's Executive Chairperson, Dr Alan Taylor, commented, "Results from cohort 2 are incredibly exciting and we look forward to seeing data from the increased dosing of 12GBq as well as discover the potential positive effects of multi-dosing on prostate cancer patients.
"Over the past few years, our research has continued to validate the pathogenic role of SGK-1 in rare arrhythmias. We now have the first in human evidence of the benefits of targeting this activated kinase to reduce prolonged QTc," commented Philip Sager, MD, Chief Medical Officer of Thryv Therapeutics. "With this initial safety and efficacy data in hand, clinical testing can commence in people with Congenital Long QT Syndrome Types 2 and 3, where chronic and substantial QTc prolongation can lead to lethal ventricular arrhythmias."
“The granting of this patent is an important component of our strategy to become a leader in the development of drugs that target critical neurodegenerative diseases,” said David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics.
BioSig has made the move to a subscription model so that electrophysiologists and cardiology departments can access the latest features with the ability to customize the rich suite of PURE EP™ software capabilities to suit their needs.
Techdow USA, a wholly owned subsidiary of Hepalink USA Inc., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), an integrated company engaged in the Development, Manufacturing and Licensing of pharmaceuticals, announced the signing of a Licensing, Supply, and Distribution agreement regarding the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection in the US market.
These approvals signify that GeneseeqPrime™ and GeneseeqPrime™ HRD are suitable for solid tumor genomic profiling, while Hemasalus™ DNA/Hemarna™ RNA is cleared for hematological cancer genomic profiling. In addition to the CE-Marked GENESEEQ multi-cancer minimal residual disease detection (Shielding™ ULTRA MRD) and GENESEEQ multi-cancer early detection (CanScan™ MCED) kits introduced earlier this year, Geneseeq currently offers five CE-marked cancer genetic testing kits tailored for various clinical situations.
The partnership between 3Z and biotx.ai aims to establish a robust bridge from animal discovery studies to human clinical trials. By utilizing comprehensive AI-powered human genetics-based modelling, the involvement of the lead therapeutic targets in ADHD will be thoroughly explored.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
